Compare CORT & HLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CORT | HLI |
|---|---|---|
| Founded | 1998 | 1972 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.7B | 9.6B |
| IPO Year | 2001 | 2015 |
| Metric | CORT | HLI |
|---|---|---|
| Price | $95.41 | $139.69 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 7 |
| Target Price | $96.50 | ★ $194.29 |
| AVG Volume (30 Days) | ★ 1.1M | 850.2K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.54% |
| EPS Growth | N/A | ★ 6.87 |
| EPS | N/A | ★ 6.22 |
| Revenue | $761,407,000.00 | ★ $2,617,516,000.00 |
| Revenue This Year | $26.08 | $13.77 |
| Revenue Next Year | $26.98 | $12.10 |
| P/E Ratio | ★ N/A | $22.16 |
| Revenue Growth | ★ 12.79 | 9.55 |
| 52 Week Low | $28.66 | $130.72 |
| 52 Week High | $97.05 | $211.78 |
| Indicator | CORT | HLI |
|---|---|---|
| Relative Strength Index (RSI) | 63.30 | 50.82 |
| Support Level | $76.41 | $133.57 |
| Resistance Level | N/A | $144.39 |
| Average True Range (ATR) | 4.17 | 4.08 |
| MACD | -0.36 | 0.42 |
| Stochastic Oscillator | 81.02 | 69.48 |
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.